drugset / Trial / NCT07015268

A Clinical Study of KLH-2109 in Patients With Endometriosis

NCT07015268

Phase 3 Active not recruiting 288 enrolled Kissei Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To verify the non-inferiority of KLH-2109 to leuprorelin acetate in a double-blind manner in terms of efficacy in endometriosis patients with pelvic pain.

Timeline

Start
2025-06-09
Primary completion
2027-11
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject KLH-2109 Unknown Oral
Comparator Leuprolide Other / unclassified Subcutaneous

Indications